TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04041505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (feeding modality)
Description: The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (feeding modality)
Description: The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
Study: NCT01034917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg dissolved in water every 24 hours
Description: Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue with the same antiretroviral regimen
Description: Continue with the same antiretroviral regimen
Study: NCT06028867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study: NCT04657159

Intervention type: OTHER
Intervention: Pain rehabilitation program
Description: Effect on health related quality of life och health-care consumption after rehabilitation

Intervention type: OTHER
Intervention: Pain rehabilitation program
Description: Effect on health related quality of life och health-care consumption after rehabilitation
Study: NCT02320019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching YH14618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14618
Study: NCT03120091

Intervention type: DEVICE
Intervention: Real-time continuous blood glucose monitoring system(CGMS)
Description: A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
Study: NCT02356835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APT001
Description: APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
Study: NCT03347994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
Study: NCT02954913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous Resection
Description: Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
Study: NCT00194012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Addressed in arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Addressed in arm description.
Study: NCT03455855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream System
Description: including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
Study: NCT00461903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perindopril
Description: Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
Study: NCT02670590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet
Description: diet
Study: NCT05158946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Future Oriented Group Training
Description: This study's experimental condition consisted of a Future Oriented Group Training (FOGT), originally developed in 2008 by van Beek et al. (2009). Participants followed this training weekly, over a period of 9 weeks in groups of 6 to 10 participants. The sessions, which lasted one and a half hours each, were each led by one trainer.
Study: NCT02864797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health related quality of life collected via CHES
Description: Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
Study: NCT05083767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The study protocol of WBV includes twelve weeks of whole-body vibration training provided to the Type 2 diabetic patients. It was recommended to all participants that they follow their regular diet and medication during the training. Two sets of six 1-minute vibration squats were designed with 20 seconds of rest, 3 times weekly for a duration 12 weeks (total workout time 36 minutes a week), using a vertical vibration machine. The six static positions consisted of (a) a deep squat position (knee angle 900) (b) an elevated squat position (knee angle 1250) (c) an elevated squat position (with elevated heels) (d) a slight knee flexion1 (hand straps with shoulder bending) (e) a slight knee flexion (hand straps with shoulder abduction) and (f) a slight knee flexion 3 (hand straps with elbow flexion). The training load steadily increased from the initial vibration of 30 Hz and the platform amplitude was raised from 2 mm at week 1 to 40 Hz and from 4 mm at week 5 to the completion of training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group was advised to their normal physical activity level, diet, and medication.
Study: NCT02805842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus BID
Description: Administration of Tacrolimus BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advagraf QD
Description: administration of Advagraf QD
Study: NCT03932474

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SAMEUp
Description: One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
Study: NCT01991184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Multiple escalating doses
Study: NCT06650241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lip Bumper Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Twin-Block Therapy
Study: NCT00774722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 10% ointment, three times daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole
Description: 10% ointment, three times daily for 14 days
Study: NCT03143829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eSSET-CINV
Description: This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
Study: NCT02985515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell training
Description: Participants will be provided with 4 vials of essential odors. Participants will sniff each scent for 20-30 seconds, twice daily, for 12 weeks. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
Study: NCT01320176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational HIV vaccine dose A
Description: The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
Study: NCT03143829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eSSET-CINV
Description: This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
Study: NCT04293887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon α1β
Description: Saline needle 2ml + recombinant human interferon α1β10ug bid nebulization inhalation
Study: NCT01400594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTU-520 Patch
Description: Terbinafine hydrochloride patch
Study: NCT01320176

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational HIV vaccine dose B
Description: The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
Study: NCT03503201

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium
Description: chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
Study: NCT01400594

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Treatment with Placebo Patch
Study: NCT04518735

Intervention type: OTHER
Intervention: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
Description: Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy

Intervention type: OTHER
Intervention: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
Description: Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy

Intervention type: OTHER
Intervention: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
Description: Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy
Study: NCT00982319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract
Description: 100 µmols of sulforaphane (dissolvable)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mango juice
Description: 150 mL of mango juice

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mango juice
Description: 150 mL of mango juice
Study: NCT03229551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
Study: NCT03859232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delta Dry® Waterproof Pantaloon
Description: Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Padding
Description: Cast with traditional cotton liner.
Study: NCT02548013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: outpatient management
Description: patients if stable will be discharged to continue treatment at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient management
Description: patients will continue there treatment in hospital till delivery
Study: NCT01766141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
Study: NCT04833569

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICG-PDT
Description: An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J was used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction. The treatment was applied according to the manufacturer's recommendation. The PDT was performed by a single operator in all test patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peri-implant mechanical debridement
Description: The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: peri-implant mechanical debridement
Description: The peri-implant mechanical debridement was done with the help of ultrasonic carbon tip (Vector, Durr Dental, Bietigheim-Bissingen, Germany).
Study: NCT03621943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped.
Study: NCT02206256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid capsules
Description: 2 times a day 1 capsule for 4 weeks before gastric bypass surgery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
Study: NCT03621943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: The umbilical cord is clamped as soon as possible and within 60 seconds of delivery.
Study: NCT01175382

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral training
Description: Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine + tamsulosin
Description: Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Behavioral + Drug Therapy
Description: Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
Study: NCT02112097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Study: NCT03791255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium silicate liner
Description: new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide liner
Description: Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
Study: NCT02756169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
Study: NCT03779282

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: see descriptions
Study: NCT01371006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose
Description: efavirenz single dosing once daily
Study: NCT01371006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal dose
Description: efavirenz once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose
Description: Efavirenz single dosing once daily
Study: NCT02804191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LO2A
Description: eye drop solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT00448110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Diclofenac (DIC075V)
Description: Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Diclofenac (DIC075V)
Description: Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac
Description: Intravenous Ketorolac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01265875

Intervention type: DRUG
Group type: OTHER
Intervention: Human Secretin
Description: Dose Escalation
Study: NCT02501330

Intervention type: DRUG
Intervention: Bosutinib
Description: The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
Study: NCT01268644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: weight based sub-cutaneous injection twice daily of Leptin
Study: NCT03891082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-Lynch
Description: A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BALLOON INSERTION
Description: Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
Study: NCT02489981

Intervention type: DRUG
Intervention: Spiriva
Description: 60 puffs
Study: NCT01241448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered Orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally